SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.80-0.1%Nov 21 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (7852)11/27/1998 3:36:00 PM
From: Bluegreen  Read Replies (2) of 17367
 
Please explain to me why Xoma's board would want to move domicile to Bermuda when it hasn't had Neuprex approved by the FDA. What other Biotechs do this sort of thing "before" approval? Do these questions have anything to do with our discussions recently? Have you thought more on how strong the anticipation might be on the possibility of Neuprex approval to make such a proposal? Also, George I don't think the company will tell you how strong their anticipation is in the prospectus, that can only be found in my opinion in their course of actions or proposed actions. Can one say that the press release could of just said for tax reasons and future collaborations and left out anticipation of possible approval of Neuprex? Would it seem that Xoma would put in the press release in anticipation of Neuprex approval to influence your vote or was it done just to publicize their anticipation?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext